[Fever of Unknown Origin in a Patient Administered With Bacillus Calmette-Guérin (BCG) to Treat Urothelial Vesical Carcinoma in Situ]

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Clinical Management Issues Pub Date : 2023-07-19 DOI:10.7175/cmi.v17i1.1543

P. Ghiringhelli, F. Macchi, Mariella Ciola, Girolamo Sala, B. Valvo, A. Agostinelli, Lorenzo Bellintani, G. Rizzo, M. Provisione, Michela Zaza, A. Diana, M. Ferrarese

引用次数: 0

Abstract

Koch’s Bacillus bovis (Mycobacterium bovis) was made avirulent by special culture conditions, i.e., 230 passages on medium containing potatoes treated with bile salts. It has been used mainly to prevent tuberculosis. The vaccine was named after the bacteriologist Albert Calmette and the veterinarian Camille Guérin, i.e., Bacillus Calmette-Guérin (BCG). These researchers worked at the Pasteur Institute in Lille and launched the vaccine in 1921.Recently, BCG was used also for its non-specific immunostimulant action. Intravesical administration of BCG is an adjunctive therapy for the treatment of bladder cancer, which does not invade the muscle wall.We will discuss the clinical case of a patient who had fever of unknown origin for about 2 months and was resistant to treatment with multiple lines of antibiotics.

查看原文本刊更多论文

[用卡介菌（BCG）治疗原位尿路上皮膀胱癌患者的不明原因发热]

通过特殊的培养条件，即在含有用胆汁盐处理的土豆的培养基上传代230次，使科赫氏牛杆菌（牛分枝杆菌）无毒。它主要用于预防肺结核。该疫苗以细菌学家Albert Calmette和兽医Camille Guérin的名字命名，即卡介苗（BCG）。这些研究人员在里尔的巴斯德研究所工作，并于1921年推出了该疫苗。最近，BCG也因其非特异性免疫刺激作用而被使用。膀胱内注射BCG是治疗膀胱癌症的一种辅助疗法，不侵犯肌肉壁。我们将讨论一名患者的临床病例，该患者因不明原因发烧约2个月，对多种抗生素治疗有耐药性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Management Issues MEDICINE, GENERAL & INTERNAL-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Clinical Management Issues is an open access, peer-reviewed journal published by SEEd Medical Publishers (online ISSN = 2283-3137). The aim of the published case reports is to expand medical knowledge, allowing a better explanation of the practical application of a clinical guideline, or including an up-to-date review of medical knowledge in that field, or helping doctors to make better decisions in a “grey area”, or explaining how to manage a disease with an integrated approach between different specialists involved. Clinical Management Issues also publishes unusual case reports (i.e. unusual side effects or adverse interactions involving medications, unexpected or unusual presentations of a disease, etc.), articles on clinical management of a disease, case series, editorials, and brief reports. Acceptance rate of submitted articles is about 90%. Content is subject to peer-review and is editorially independent. This journal provides immediate open access to all of its articles (both HTML and PDF versions). Authors are asked to state any professional and financial situations that might be perceived as causing a conflict of interest with respect to integrity of content. The Declaration of Financial Competing Interests, that should be filled, signed and sent to the Publisher, is downloadable here.